Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 67.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 310,213 shares of the company’s stock after acquiring an additional 124,913 shares during the period. The Manufacturers Life Insurance Company owned about 0.14% of Gossamer Bio worth $279,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Sivia Capital Partners LLC acquired a new stake in Gossamer Bio in the 1st quarter valued at $29,000. SG Americas Securities LLC purchased a new stake in shares of Gossamer Bio during the first quarter worth about $34,000. Choreo LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter worth about $46,000. Sequoia Financial Advisors LLC lifted its stake in Gossamer Bio by 27.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after buying an additional 20,000 shares in the last quarter. Finally, Financial Advocates Investment Management boosted its holdings in Gossamer Bio by 57.5% in the 2nd quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock worth $96,000 after buying an additional 39,000 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on GOSS shares. Oppenheimer began coverage on Gossamer Bio in a report on Tuesday, June 25th. They set an “outperform” rating and a $9.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, September 17th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $0.96 on Friday. Gossamer Bio, Inc. has a fifty-two week low of $0.45 and a fifty-two week high of $1.60. The firm has a market capitalization of $217.74 million, a P/E ratio of -0.91 and a beta of 1.96. The stock’s fifty day moving average is $0.93 and its two-hundred day moving average is $0.87. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.21 and a current ratio of 8.21.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $95.84 million for the quarter, compared to analysts’ expectations of $160.00 million. On average, research analysts anticipate that Gossamer Bio, Inc. will post -0.33 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.